期刊文献+

EZH2抑制剂DZNEP影响人头颈部鳞癌增殖与凋亡的体内外研究 被引量:3

DZNEP inhibits cell proliferation and induces apoptosis by targeting EZH2 in human head and neck squamous cell carcinoma in vitro and vivo
下载PDF
导出
摘要 目的:探讨Zeste同源序列2的增强子(EZH2)的小分子抑制剂DZNEP抑制人头颈部鳞状细胞癌细胞Tb3.1增殖、诱导凋亡的效果与机制。方法:甲基噻唑基四唑(MTT)法测细胞对DZNEP的半数致死量(IC50)、细胞的增殖能力;流式细胞术检测细胞凋亡;平板克隆法检测细胞形成克隆能力;JC-1荧光探针染色法检测细胞线粒体膜电位;蛋白质印迹法(WB)检测EZH2、细胞增殖核抗原(Ki-67)、B细胞淋巴瘤2(Bcl-2、BAX)、活化型含半胱氨酸的天冬氨酸蛋白水解酶3(CCASP-3)的表达。体内实验裸鼠皮下荷瘤模型,通过免疫组织化学染色及原位末端标记(TUNEL)法检测DZNEP对细胞增殖、凋亡的作用。结果:经DZNEP处理后,EZH2蛋白表达降低;MTT法检测DZNEP明显抑制鳞癌细胞Tb3.1的增殖,且具有浓度和时间依赖性;流式细胞术显示DZNEP可诱导细胞凋亡;平板克隆实验表明DZNEP能够明显抑制克隆形成能力,抑制细胞增殖;JC-1荧光探针染色法显示DZNEP可以改变细胞的线粒体膜电位;WB显示,DZNEP可增加促凋亡基因(CCASP-3、BAX)的表达,抑制Ki-67、Bcl-2的表达水平。体内实验观察结束时,DZNEP处理组肿瘤体积较对照组明显减小。免疫组织化学染色结果示,DZNEP组中BAX、CCASP-3表达增加,Ki-67、Bcl-2表达减少;TUNEL结果显示,DZNEP组比DMSO组肿瘤细胞凋亡指数上升。结论:DZNEP通过抑制EZH2表达在体外抑制Tb3.1细胞增殖并诱导凋亡;为进一步探讨EZH2参与人头颈部鳞状细胞癌发生发展的分子机制提供科学实验依据。 Objective:To investigate the anti-tumour molecular mechanism of DZNEP in human head and neck squamous cell carcinoma. Methods:Tb3.1 human head and neck squamous cell carcinoma cell lines were employed. DZNEP was used to suppress the expression of EZH2. Methyl thiazolyl tatrozolium (MTT) assay was applied to determine IC50 and cell survival. Flow cytometry(FCM) was used to measure cell apoptosis. JC-1 fluorescence was employed to determine MMP. The expression level of EZH2 , antigen 67(Ki-67), B cell lymphoma 2 (Bcl-2, BAX) and cleaved cysteinyl aspartate specific proteinase-3(CCASP-3) were examined by Western blotting. Results:Compared with control and normal control cells, DZNEP inhibited EZH2 expression and affected cell proliferation. Apoptosis rate was elevated by DZNEP. Clone formation assay suggested that cell clone numbers were significantly reduced by DZNEP. BAX and CCASP-3 expression were enhanced by DZNEP treatment, while Ki-67 and Bcl-2 expression were suppressed. In vivo, the tumor volume after treatment with DZNEP was significantly smaller than control groups. Immunological histological chemistry suggested that BAX and CCASP-3 protein expression was up-regulated while Ki-67 and Bcl-2 protein of tumor tissue was down-regulated after treated DZNEP as compared to control groups. TUNEL assay indicated that apoptosis index was increased after treatment with DZNEP compared with control groups. Conclusion:DZNEP modulates proliferation and apoptosis of Tb3.1 cancer cell by inhibiting EZH2, which might promote further research in head and neck squamous cell carcinoma treatment.
出处 《天津医科大学学报》 2015年第6期461-465,共5页 Journal of Tianjin Medical University
基金 国家自然科学基金资助项目(81172573)
关键词 头颈部鳞状细胞癌 EZH2 细胞凋亡 细胞增殖 head and neck squamous cell carcinoma EZH2 apoptosis proliferation
  • 相关文献

参考文献16

  • 1Ezhkova E, Pasolli H A, Parker J S, et al. Ezh2 orchestrates gene expression for the stepwise differentiation of tissue-specific stem cells[J]. Cell, 2009, 136(6): 1122.
  • 2Vire E, Brenner C, Deplus R, et al. The polycomb group protein EZH2 directly controls DNA methylation[J]. Nature, 2006, 439(7078): 871.
  • 3Strojan P, Vermorken J B, Beitler J J, et al. Cumulative cisplatin dose in concurrent chemoradiotherapy for head and neck cancer:A systematic review[J]. Head Neck, 2015, [Epub ahead of print].
  • 4Safdari Y, Khalili M, Farajnia S A, et al. Recent advances in head and neck squamous cell carcinoma - A review [J]. Clin Biochem, 2014, 47(13/14): 1195.
  • 5Burz C, Berindan-Neagoe I, Balacescu O, et al. Apoptosis in cancer: key molecular signaling pathways and therapy targets [J]. Acta Oncol, 2009, 48(6): 811.
  • 6Nakagawa S, Sakamoto Y, Okabe H, et al. Epigenetic therapy with the histone methyltransferase EZH2 inhibitor 3-deazaneplanocin A inhibits the growth of cholangiocarcinoma cells[J]. Oncol Rep, 2014, 31(2): 983.
  • 7Wang C, Liu X Q, Chen Z J, et al. Polycomb group protein EZH2- mediated E-cadherin repression promotes metastasis of oral tongue squamous cell carcinoma[J]. Mol Carcinog, 2013, 52(3): 229.
  • 8Cao W, Feng Z, Cui Z B, et al. Up-regulation of enhancer of zeste homolog 2 is associated positively with cyclin D1 overexpression and poor clinical outcome in head and neck squamous cell carcinoma[J]. Cancer, 2012, 118(11): 2858.
  • 9Fiskus W, Rao R, Balusu R, et al. Superior efficacy of a combined epigenetic therapy against human mantle cell lymphoma cells [J]. Clin Cancer Res, 2012, 18(22): 6227.
  • 10Xie Z G, Bi C L, Cheong L L, et al. Determinants of sensitivity to DZNep induced apoptosis in multiple myeloma cells[J]. PLoS One, 2011, 6(6): e21583.

同被引文献37

  • 1闫冰冰,李力.DNA甲基化与卵巢癌多药耐药及预后的关系[J].中国肿瘤生物治疗杂志,2015,22(3):281-289. 被引量:7
  • 2Siegel RL,Miller KD,Jemal A. Cancer statistics,2016[ J]. CA Cancer J Clin,2016 ;66( 1 ) :7-30.
  • 3Liu TP, Hang YH, Tung KY, et al. In silieo and experimemal analyses predict the therapeutic value of an EZH2 inhibitor GSK343 against hepa- tocellular carcinoma through the induction of metallothionein genes[ J ]. Oncoscience ,2016 ;3 ( 1 ) :9-20.
  • 4Liu S,Chen D,Shen W,et al. EZH2 mediates the regulation of S100A4 on E-eadherin expression and the proliferation, migration of gastric cancer cells [ J ]. Hepatogastroenterology, 2015 ;62 ( 139 ) : 737 -41.
  • 5Sun S,Yu F, Zhang L, et al. EZH2, an on-off valve in signal network of tumor cells[ J]. Cell Signal ,2016 ;28 (5) :481-7.
  • 6Wei FZ,Cao Z,Wang X,et al. Epigenetie regulation of autophagy by the methyhransferase EZH2 through an MTOR-dependent pathway[ J). Auto- phagy ,2015 ; 11 ( 12 ) :2309 -22.
  • 7Riquelme E, Behrens C, Lin HY, et al. Modulation of EZH2 expression by MEK-ERK or PI3K-AKT signaling in lung cancer is dictated by dif- ferent KRAS oncogene mutations [ J ]. Cancer Res, 2016; 76 ( 3 ) : 675 -85.
  • 8Jung HY, Jun S, Lee M,et al. PAF and EZH2 induce Wnt/β-catenin signaling hyperactivation [ J ]. Mol Cell,2013 ;52 (2) : 193-205.
  • 9陈礼忠,於建鹏.5-氮-2'脱氧胞苷对食管癌细胞系KYSE220中CDH13基因甲基化的影响[J].中国医药指南,2012,10(3):69-70. 被引量:1
  • 10王丽,汪竹,袁昕,焦南林,张有为,童建东.结直肠癌中CDH13基因甲基化及其临床意义[J].江苏医药,2012,38(2):199-201. 被引量:3

引证文献3

二级引证文献6

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部